Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
UroGen Pharma Ltd. - Ordinary Shares
(NQ:
URGN
)
39.31
-0.20 (-0.51%)
Streaming Delayed Price
Updated: 2:52 PM EDT, Jul 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about UroGen Pharma Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
Next >
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
↗
July 12, 2026
Mark Schoenberg's final disposition under a pre-established Rule 10b5-1 plan follows 191% annual returns, leaving him with 119,763 shares worth $4.82 million.
Via
The Motley Fool
Topics
Regulatory Compliance
Urogen Pharma (NASDAQ:URGN) Nears 52-Week High on Minervini Trend Template and High Growth Momentum Screen
↗
July 09, 2026
Via
Chartmill
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
↗
June 30, 2026
Focused on innovative cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
↗
June 14, 2026
Focused on urinary tract cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth
↗
June 08, 2026
Via
Chartmill
UroGen Pharma (NASDAQ:URGN) Crushes Q1 Estimates as ZUSDURI Momentum Accelerates
↗
May 06, 2026
Via
Chartmill
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q4 2025 Results Amid Strong Commercial Progress
↗
March 02, 2026
Via
Chartmill
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
↗
May 23, 2026
This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
↗
May 23, 2026
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.
Via
The Motley Fool
UroGen (URGN) Q1 2026 Earnings Transcript
↗
May 07, 2026
UroGen (URGN) Q1 2026 Earnings Transcript
Via
The Motley Fool
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?
↗
March 23, 2026
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
Via
The Motley Fool
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain
↗
March 18, 2026
Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.
Via
The Motley Fool
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?
↗
March 18, 2026
This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.
Via
The Motley Fool
Topics
Regulatory Compliance
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
↗
March 18, 2026
This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish
↗
March 18, 2026
This clinical-stage biotech develops therapies for CML, NASH, and obesity.
Via
The Motley Fool
Topics
Regulatory Compliance
UroGen (URGN) Q4 2025 Earnings Call Transcript
↗
March 02, 2026
UroGen (URGN) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally
↗
December 26, 2025
A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter.
Via
The Motley Fool
Topics
Death
Regulatory Compliance
UroGen (URGN) Q3 2025 Earnings Call Transcript
↗
November 06, 2025
UroGen (URGN) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Q3 2025 Earnings: Revenue Misses, Loss Per Share Beats
↗
November 06, 2025
UroGen Q3 2025 results show a revenue miss but a narrower-than-expected loss. The biopharma highlighted strong pipeline progress and the ongoing launch of its new product, ZUSDURI.
Via
Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 24, 2025
Via
Benzinga
UroGen (URGN) Q2 Revenue Rises 11%
↗
August 07, 2025
Via
The Motley Fool
Topics
Intellectual Property
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q2 2025 Earnings Amid Widening Losses and Revenue Beat
↗
August 07, 2025
UroGen Pharma (URGN) reported Q2 2025 revenue of $24.2M, beating estimates, but EPS missed at -$1.05. JELMYTO sales grew 11% YoY, while ZUSDURI launch and R&D costs widened losses. Shares dipped...
Via
Chartmill
3 Bullish Biotech Stocks With Explosive Growth Trends
↗
July 21, 2025
These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies
Via
MarketBeat
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday
↗
June 16, 2025
Via
Benzinga
US Stocks Likely To Rebound After Sharp Decline Amid Israel-Iran Conflict: S&P 500 Historically Moves Higher After Wars, Says Expert
↗
June 16, 2025
U.S. stock futures were trading higher on Monday following Friday's sharp declines. Futures of benchmark indices were higher in premarket.
Via
Benzinga
Topics
Stocks
UroGen Pharma Stock Scores Bullish Price Target Revisions Up To $47 Following FDA Nod For Zusduri
↗
June 16, 2025
UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer.
Via
Stocktwits
Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week
↗
June 13, 2025
UroGen Pharma shares are surging this week after the company gained FDA approval for ZUSDURI. The positive clinical trial results and an analyst upgrade fueled a significant stock price increase.
Via
Benzinga
Top movers in Friday's session
↗
June 13, 2025
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
